ESR1 and breast cancer: Comparative analyses of estrogen receptor-positive (ER+) metastatic BC (mBC) have demonstrated genomic evolution during metastatic progression, and following treatment, such as the enrichment of HER2 and ESR1 genomic alterations (GAs) [2, 3].